Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

NCT06724263 is registered in ClinicalTrials.gov with Tasly Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06724263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06724263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
August 31, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancers, colorectal cancer, hepatocellular carcinoma (hcc), non-squamous non-small cell lung cancer, recurrent platinum-resistant epithelial ovarian cancer, small cell lung cancer, triple negative breast cancer (tnbc)